{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:33:56Z","timestamp":1782192836555,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"AstraZeneca Farmac\u00e9utica Spain, S.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04015-8","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T17:11:22Z","timestamp":1755018682000},"page":"494-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1827-6323","authenticated-orcid":false,"given":"Mar\u00eda Carmen","family":"Areses Manrique","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Le\u00f3n-Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Silva-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"L\u00e1zaro-Quintela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Fern\u00e1ndez N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Afonso-Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Freijido-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Fern\u00e1ndez-Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Cameselle-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Gonz\u00e1lez-Ojea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Huidobro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"T\u00e1vara-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carme","family":"Garc\u00eda-Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cordeiro Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Garc\u00eda Mata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Azpitarte-Raposeiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Ruiz de Almir\u00f3n Lomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Cebey-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mosquera Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Santom\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Amenedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"F\u00edrvida-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"4015_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"4015_CR2","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/jto.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243\u201360. https:\/\/doi.org\/10.1097\/jto.0000000000000630.","journal-title":"J Thorac Oncol"},{"key":"4015_CR3","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.gendis.2022.07.023","volume":"10","author":"H Padinharayil","year":"2023","unstructured":"Padinharayil H, Varghese J, John MC, Rajanikant GK, Wilson CM, Al-Yozbaki M, et al. Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. Genes Dis. 2023;10:960\u201389. https:\/\/doi.org\/10.1016\/j.gendis.2022.07.023.","journal-title":"Genes Dis"},{"key":"4015_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:339\u201357. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.009.","journal-title":"Ann Oncol"},{"key":"4015_CR5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.21037\/atm-20-2925","volume":"9","author":"Y Chen","year":"2021","unstructured":"Chen Y, Deng J, Liu Y, Wang H, Zhao S, He Y, et al. Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Ann Transl Med. 2021;9:206. https:\/\/doi.org\/10.21037\/atm-20-2925.","journal-title":"Ann Transl Med"},{"key":"4015_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","volume":"26","author":"B Melosky","year":"2022","unstructured":"Melosky B, Kambartel K, H\u00e4ntschel M, Bennetts M, Nickens DJ, Brinkmann J, et al. Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis. Mol Diagn Ther. 2022;26:7\u201318. https:\/\/doi.org\/10.1007\/s40291-021-00563-1.","journal-title":"Mol Diagn Ther"},{"key":"4015_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/jjco\/hyad052","volume":"53","author":"T Araki","year":"2023","unstructured":"Araki T, Kanda S, Horinouchi H, Ohe Y. Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance. Jpn J Clin Oncol. 2023;53:547\u201361. https:\/\/doi.org\/10.1093\/jjco\/hyad052.","journal-title":"Jpn J Clin Oncol"},{"key":"4015_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102664","volume":"122","author":"F Ciardiello","year":"2024","unstructured":"Ciardiello F, Hirsch FR, Pirker R, Felip E, Valencia C, Smit EF. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer. Cancer Treat Rev. 2024;122: 102664. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102664.","journal-title":"Cancer Treat Rev"},{"key":"4015_CR9","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","volume":"33","author":"A Passaro","year":"2022","unstructured":"Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022;33:466\u201387. https:\/\/doi.org\/10.1016\/j.annonc.2022.02.003.","journal-title":"Ann Oncol"},{"key":"4015_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biom9110668","author":"I Solassol","year":"2019","unstructured":"Solassol I, Pinguet F, Quantin X. FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: safety, tolerability, plasma concentration monitoring, and management. Biomolecules. 2019. https:\/\/doi.org\/10.3390\/biom9110668.","journal-title":"Biomolecules"},{"key":"4015_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/17512433.2017.1265446","volume":"10","author":"K Soejima","year":"2017","unstructured":"Soejima K, Yasuda H, Hirano T. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer. Expert Rev Clin Pharmacol. 2017;10:31\u20138. https:\/\/doi.org\/10.1080\/17512433.2017.1265446.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"4015_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1612674.","journal-title":"N Engl J Med"},{"key":"4015_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med"},{"key":"4015_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662.","journal-title":"N Engl J Med"},{"key":"4015_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2217\/fon-2022-0919","volume":"19","author":"P Cheema","year":"2023","unstructured":"Cheema P, Cho BC, Freitas H, Provencio M, Chen YM, Kim SW, et al. A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data. Future Oncol. 2023;19:61\u201375. https:\/\/doi.org\/10.2217\/fon-2022-0919.","journal-title":"Future Oncol"},{"key":"4015_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12885-021-07922-5","volume":"21","author":"M Provencio","year":"2021","unstructured":"Provencio M, Terrasa J, Garrido P, Campelo RG, Aparisi F, Diz P, et al. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group. BMC Cancer. 2021;21:230. https:\/\/doi.org\/10.1186\/s12885-021-07922-5.","journal-title":"BMC Cancer"},{"key":"4015_CR17","doi-asserted-by":"publisher","first-page":"100058","DOI":"10.1016\/j.esmorw.2024.100058","volume":"5","author":"Y Uehara","year":"2024","unstructured":"Uehara Y, Takeyasu Y, Yoshida T, Tateishi A, Torasawa M, Hosomi Y, et al. Real-world outcomes of treatment strategy between first-line osimertinib, first\/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC. ESMO Real World Data Digit Oncol. 2024;5:100058. https:\/\/doi.org\/10.1016\/j.esmorw.2024.100058.","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"4015_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061079","author":"H Viray","year":"2024","unstructured":"Viray H, Piper-Vallillo AJ, Widick P, Academia E, Shea M, Rangachari D, et al. A real-world study of patient characteristics and clinical outcomes in EGFR mutated lung cancer treated with first-line osimertinib: expanding the FLAURA trial results into routine clinical practice. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16061079.","journal-title":"Cancers (Basel)"},{"key":"4015_CR19","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.21037\/tlcr-23-577","volume":"12","author":"D Zhang","year":"2023","unstructured":"Zhang D, Liu X, Shen F, Zhao D, Shi Y, Zhang H, et al. Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study. Transl Lung Cancer Res. 2023;12:2229\u201344. https:\/\/doi.org\/10.21037\/tlcr-23-577.","journal-title":"Transl Lung Cancer Res"},{"key":"4015_CR20","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.2217\/fon-2020-0203","volume":"16","author":"F Imamura","year":"2020","unstructured":"Imamura F, Kimura M, Yano Y, Mori M, Suzuki H, Hirashima T, et al. Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation. Future Oncol. 2020;16:1537\u201347. https:\/\/doi.org\/10.2217\/fon-2020-0203.","journal-title":"Future Oncol"},{"key":"4015_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100720","volume":"5","author":"K Watanabe","year":"2024","unstructured":"Watanabe K, Hosomi Y, Naoki K, Nakahara Y, Tsukita Y, Matsumoto H, et al. The whole picture of first-line osimertinib for EGFR mutation-positive advanced NSCLC: real-world efficacy, safety, progression pattern, and posttreatment therapy (Reiwa Study). JTO Clin Res Rep. 2024;5: 100720. https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100720.","journal-title":"JTO Clin Res Rep"},{"key":"4015_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 11). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"4015_CR23","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. June 14 c-ehenngfCCC."},{"key":"4015_CR24","unstructured":"English MedDRA Version 27.0. 2024. https:\/\/www.meddra.org\/news-and-events\/news\/english-meddra-version-270-now-available. Accessed 2 Dec 2024."},{"key":"4015_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071414","author":"E Kokkotou","year":"2024","unstructured":"Kokkotou E, Anagnostakis M, Evangelou G, Syrigos NK, Gkiozos I. Real-world data and evidence in lung cancer: a review of recent developments. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16071414.","journal-title":"Cancers (Basel)"},{"key":"4015_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/onco.13951","volume":"27","author":"M Lorenzi","year":"2022","unstructured":"Lorenzi M, Ferro A, Cecere F, Scattolin D, Del Conte A, Follador A, et al. First-line osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: outcome and safety in the real world: FLOWER study. Oncologist. 2022;27:87-e115. https:\/\/doi.org\/10.1002\/onco.13951.","journal-title":"Oncologist"},{"key":"4015_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100592","volume":"27","author":"RGP Gijtenbeek","year":"2023","unstructured":"Gijtenbeek RGP, Damhuis RAM, van der Wekken AJ, Hendriks LEL, Groen HJM, van Geffen WH. Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study. Lancet Reg Health Eur. 2023;27: 100592. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100592.","journal-title":"Lancet Reg Health Eur"},{"key":"4015_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100636","volume":"5","author":"Y Takeyasu","year":"2024","unstructured":"Takeyasu Y, Yoshida T, Masuda K, Matsumoto Y, Shinno Y, Okuma Y, et al. Distinct progression and efficacy of first-line osimertinib treatment according to mutation subtypes in metastatic NSCLC harboring EGFR mutations. JTO Clin Res Rep. 2024;5: 100636. https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100636.","journal-title":"JTO Clin Res Rep"},{"key":"4015_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100646","volume":"33","author":"S Agraso","year":"2022","unstructured":"Agraso S, L\u00e1zaro M, Firvida XL, Santom\u00e9 L, Fern\u00e1ndez N, Azpitarte C, et al. Real-world data with afatinib in Spanish patients with treatment-na\u00efve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): clinical experience of the Galician Lung Cancer Group. Cancer Treat Res Commun. 2022;33: 100646. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100646.","journal-title":"Cancer Treat Res Commun"},{"key":"4015_CR30","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389:1935\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2306434.","journal-title":"N Engl J Med"},{"key":"4015_CR31","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","volume":"391","author":"BC Cho","year":"2024","unstructured":"Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024;391:1486\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2403614.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04015-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04015-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04015-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:47:10Z","timestamp":1769694430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04015-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4015"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04015-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests\/personal relationships, which may be considered potential competing interests: M\u00aa Carmen Areses has received honoraria for educational activities or advisory roles from AstraZeneca, Bristol-Myers Squibb,\u00a0Boehringer Ingelheim,\u00a0Merck,\u00a0MSD, Novartis,\u00a0Pfizer,\u00a0PierreFabre, Roche, Sanofi, and Takeda, and has received travel accommodations and expenses from AstraZeneca, Bristol-Myers Squibb, MSD, Roche, Sanofi, and Takeda. Luis Le\u00f3n-Mateos has received consulting fees from AstraZeneca, Bristol-Myers Squib, Merck, MSD, Roche, Sanofi, and Takeda; has received payment or honoraria for lectures, presentations, manuscript writing, and participation in speakers\u2019 bureaus and educational events from AstraZeneca, Bristol-Myers Squib, Jansen, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, and Takeda; and has received support for attending meetings and\/or travel accommodations from AstraZeneca, Bristol-Myers Squib, Jansen, MSD, Pfizer, Roche, Sanofi, and Takeda. Sofia Silva-Diaz received speaker honoraria from LEO Pharma. Ana Alonso received speaker honoraria from Roche, and Bristol-Myers Squibb. Martin L\u00e1zaro-Quintela has received advisory board member fees from Ipsen, Bristol-Myers Squibb, Bayer, Merck, Beigene, and Novartis; speaker honoraria from Amgen, Roche, Astra-Zeneca, Lilly, Bristol-Myers Squibb, MSD, Ipsen, and Janssen; and travel grants from Ipsen, Roche, MSD, and Bristol-Myers Squibb. Natalia Fern\u00e1ndez Nu\u00f1ez received speaker-honoraria from AstraZeneca. Francisco Javier Afonso Afonso has received consultant and\/or speaking and\/or advisory roles from AstraZeneca, Pfizer, Bristol-Myers Squib, MSD, Roche, Ipsen, Sanofi, Novartis, and Boehringer, and has received grants or travel support from MSD, Pfizer, Sanofi, Bristol-Myers Squib, Takeda, and Roche. Pablo Freijido-\u00c1lvarez declares no conflicts of interest. Manuel Fern\u00e1ndez-Bruno declares no conflicts of interest. Soledad Cameselle-Garc\u00eda has received speaker honoraria from Amgen, Rovi, and Pfizer, and has received support for attending meetings and\/or travel grants from AstraZeneca, Bristol-Myers Squib, MSD, Roche, and Rovi. Clara Gonz\u00e1lez-Ojea declares no conflicts of interest. Gerardo Huidobro declares no conflicts of interest. Blanca T\u00e1vara Silva declares no conflicts of interest. Carme Garc\u00eda-Lorenzo declares no conflicts of interest. Javier \u00c1lvarez declares no conflicts of interest. Patricia Cordeiro Gonz\u00e1lez declare that they have no conflicts of interest. Jes\u00fas Garc\u00eda Mata was also awarded. Cristina Azpitarte-Raposeiras has received speaker honoraria from Bristol-Myers Squib, Merck, Takeda, Janssen, AstraZeneca, Roche, Lilly, Bayer, MSD, and Ipsen, and has received travel grants from Roche, MSD, Lilly, Ipsen, AstraZeneca, Takeda, Bayer, and Merck. Luis Ruiz de Almir\u00f3n Lomo has received consulting fees and honoraria for educational events from AstraZeneca, Bristol-Myers Squib, Merck, Novartis, Pierre-Fabre, Roche, Lilly, and Pfizer and has received support for attending meetings and\/or travel grants from Pfizer, AstraZeneca, Roche, Sanofi, Gilead, and Novartis. V\u00edctor Cebey-L\u00f3pez declare that they have no conflicts of interest. Joaqu\u00edn Mosquera Mart\u00ednez declares no conflicts of interest. Jorge Garc\u00eda-Gonz\u00e1lez has received consulting fees and honoraria for educational events from AstraZeneca, Bristol-Myers Squib, Jansen, Merck, Novartis, Pierre-Fabre, Roche, Sanofi, and Takeda and has received support for attending meetings and\/or travel grants from AstraZeneca, Bristol-Myers Squib, Jansen, MSD, Roche, Rovi, Sanofi, and Takeda. Luc\u00eda Santom\u00e9 has received advisory board member fees from Pfizer, and travel and\/or education grants from AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Merck Serono, Bayer, Ipse, Janssen, and Astellas. Margarita Amenedo has received honoraria for presentations and participation in speakers'bureaus from AstraZeneca, MSD, and Pharmamar, and has received support for attending meetings from GSK, Lilly, and AstraZeneca. Jos\u00e9 Luis F\u00edrvida-P\u00e9rez received advisory board member fees from BeiGene, Boehringer, Sanofi, and Takeda, and speaker honoraria from Astra, Bristol-Myers Squib, Boehringer, Lilly, MSD, Pfizer, Roche, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was reviewed and approved by the Local Research Ethics Committee of the Autonomous Community of Galicia (Spain).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all the participants before enrollment in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}